Seres Therapeutics, Inc. (MCRB): Price and Financial Metrics


Seres Therapeutics, Inc. (MCRB): $3.57

0.16 (+4.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MCRB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MCRB POWR Grades


  • MCRB scores best on the Value dimension, with a Value rank ahead of 89.2% of US stocks.
  • The strongest trend for MCRB is in Value, which has been heading up over the past 179 days.
  • MCRB ranks lowest in Momentum; there it ranks in the 4th percentile.

MCRB Stock Summary

  • Price to trailing twelve month operating cash flow for MCRB is currently 102.77, higher than 95.66% of US stocks with positive operating cash flow.
  • Revenue growth over the past 12 months for Seres Therapeutics Inc comes in at 336.33%, a number that bests 97.61% of the US stocks we're tracking.
  • In terms of volatility of its share price, MCRB is more volatile than 96.53% of stocks we're observing.
  • Stocks that are quantitatively similar to MCRB, based on their financial statements, market capitalization, and price volatility, are AGLE, CHRS, CRIS, FUSN, and VYGR.
  • Visit MCRB's SEC page to see the company's official filings. To visit the company's web site, go to www.serestherapeutics.com.

MCRB Valuation Summary

  • MCRB's price/sales ratio is 19.6; this is 415.79% higher than that of the median Healthcare stock.
  • MCRB's price/earnings ratio has moved up 73.9 over the prior 75 months.
  • MCRB's EV/EBIT ratio has moved up 76.6 over the prior 75 months.

Below are key valuation metrics over time for MCRB.

Stock Date P/S P/B P/E EV/EBIT
MCRB 2021-08-31 19.6 5.8 -4.4 -4.3
MCRB 2021-08-30 18.8 5.6 -4.3 -4.1
MCRB 2021-08-27 19.1 5.7 -4.3 -4.2
MCRB 2021-08-26 18.5 5.5 -4.2 -4.0
MCRB 2021-08-25 18.9 5.6 -4.3 -4.2
MCRB 2021-08-24 19.1 5.7 -4.3 -4.2

MCRB Growth Metrics

    Its 3 year revenue growth rate is now at 1066.68%.
  • Its 5 year cash and equivalents growth rate is now at -71.83%.
  • The year over year net cashflow from operations growth rate now stands at -44.57%.
Over the past 70 months, MCRB's revenue has gone up $142,217,000.

The table below shows MCRB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 144.927 6.688 -65.578
2021-09-30 155.27 40.624 -33.829
2021-06-30 29.962 -112.984 -132.327
2021-03-31 30.744 -98.855 -104.711
2020-12-31 33.215 -93.61 -89.127
2020-09-30 23.273 -89.73 -89.653

MCRB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MCRB has a Quality Grade of C, ranking ahead of 46.12% of graded US stocks.
  • MCRB's asset turnover comes in at 0.094 -- ranking 268th of 680 Pharmaceutical Products stocks.
  • ABEO, VXRT, and ARWR are the stocks whose asset turnover ratios are most correlated with MCRB.

The table below shows MCRB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.094 1 -0.662
2021-03-31 0.111 1 -0.642
2020-12-31 0.146 1 -0.751
2020-09-30 0.133 1 -1.134
2020-06-30 0.247 1 -1.379
2020-03-31 0.276 1 -1.299

MCRB Price Target

For more insight on analysts targets of MCRB, see our MCRB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.57 Average Broker Recommendation 1.5 (Moderate Buy)

MCRB Stock Price Chart Interactive Chart >

Price chart for MCRB

MCRB Price/Volume Stats

Current price $3.57 52-week high $25.06
Prev. close $3.41 52-week low $3.22
Day low $3.24 Volume 1,026,400
Day high $3.57 Avg. volume 800,741
50-day MA $5.78 Dividend yield N/A
200-day MA $7.11 Market Cap 329.26M

Seres Therapeutics, Inc. (MCRB) Company Bio


Seres Therapeutics is a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company was founded in 2010 and is based in Cambridge, Massachusetts.


MCRB Latest News Stream


Event/Time News Detail
Loading, please wait...

MCRB Latest Social Stream


Loading social stream, please wait...

View Full MCRB Social Stream

Latest MCRB News From Around the Web

Below are the latest news stories about Seres Therapeutics Inc that investors may wish to consider to help them evaluate MCRB as an investment opportunity.

Seres Therapeutics to Present at Chardan Metagenomics and Microbiome Medicines Summit

CAMBRIDGE, Mass., February 22, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will present at the Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022 at 2:00 p.m. ET.

Yahoo | February 22, 2022

Seres Therapeutics to Host Fourth Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on March 1, 2022

CAMBRIDGE, Mass., February 22, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 1, 2022 at 8:30 a.m. ET to discuss fourth quarter and full year 2021 results and provide a general business update.

Yahoo | February 22, 2022

INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors.

Yahoo | February 15, 2022

Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer

CAMBRIDGE, Mass., February 08, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Paula Cloghessy, SPHR, SHRM-SCP, has joined Seres as Executive Vice President, Chief People Officer effective February 7, 2022, reporting directly to Eric Shaff, President and Chief Executive Officer.

Yahoo | February 8, 2022

Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Yahoo | February 1, 2022

Read More 'MCRB' Stories Here

MCRB Price Returns

1-mo -31.87%
3-mo N/A
6-mo -62.77%
1-year -83.22%
3-year -12.93%
5-year -63.61%
YTD -57.14%
2021 -66.00%
2020 610.14%
2019 -23.67%
2018 -55.42%
2017 2.42%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5294 seconds.